Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Codex update

This article was originally published in The Tan Sheet

Executive Summary

The Codex Committee of General Principles decides April 3 in Paris not to include the precautionary principle in Codex's draft risk analysis standards for food safety. The principle allows "governments to take certain preventive measures for foods in cases where scientific evidence on the safety of the food is uncertain," says the International Alliance of Dietary Supplement-Food Association. By excluding the principle, a "fair opportunity" is assured for trade in supplement products, says the Council for Responsible Nutrition. The principle's inclusion has been discussed before (1"The Tan Sheet" Oct. 31, 2005, p. 11). IADSA says Codex is at an intermediate stage and attempts could come to include the principle during the next commission meeting later this year...

You may also be interested in...

Trade Groups Push For Codex Health Claims Scientific Basis Guidelines

CRN's John Hathcock, PhD, urged the U.S. and other delegations to Codex's nutrition committee to "move forward" with the "Guidelines on the Scientific Basis of Health Claims" at an Oct. 18 public meeting

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts